

MANAGEMENT OF CANCER BLADDER

Essay Submitted for the Partial Fulfillment of Master Degree
in Radiotherapy and Nuclear Medicine

By

Dina Ahmed Salem

M.B., B.Ch.

Supervised by

Prof. Dr. Atef Youssef Rjad

Professor of Radiation Oncology and Nuclear Medicine

Ain Shams University

Prof. Dr. Abd El-Hamid Abd El-Kader Youssef

Professor of Urosurgery

Ain Shams University

Faculty of Medicine

Ain Shams University

1998



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

**قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا،
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ**

صَدَقَ اللَّهُ الْعَظِيمُ

سورة البقرة- الآية: ٣٢


Acknowledgment

First of all, thanks to God, without his help this work could not be accomplished.

I would like to express my sincere gratitude and appreciation to Prof. Dr. Atef Youssef Riad, Professor of Radiation Oncology and Nuclear Medicine, Ain Shams University, for his valuable knowledge, great help, meticulous supervision and kind encouragement during this work. Words of thanks are little to express my gratefulness for him.

I would like also to thank Prof. Dr. Abd El-Hamid Abd El-Kader Youssef, Professor of Urosurgery, Ain Shams University, for his sincere help, continuous support and his worthy knowledge which have been of paramount importance to complete this work.

Dina Ahmed



*To my beloved father who is always
behind any of my successes*

List of Figures

	Page
• Fig. (1): Median section of a male pelvis showing the anatomical relations of the urinary bladder	4
• Fig. (2): Median section of a female pelvic showing the anatomical relations of the urinary bladder	4
• Fig. (3): Arterial supply of the bladder	9
• Fig. (4): Lymph drainage of the bladder	10
• Fig. (5): Nerve supply of the bladder	11
• Fig. (6): Relative frequency of cancer bladder in the national cancer institute (NCI) in Cairo	14
• Fig. (7): Relative frequency of cancer bladder in Ain Shams University Hospitals	14
• Fig. (8): Overview of arylamine-induced bladder cancer pathology	21
• Fig. (9): Papillary transitional cell carcinoma (macroscopic appearance)	26
• Fig. (10): Papillary transitional cell carcinoma (microscopic appearance)	27
• Fig. (11): Carcinoma in situ (gross appearance)	29
• Fig. (12): Carcinoma in situ (microscopic appearance)	30
• Fig. (13): Infiltrative transitional cell carcinoma of the bladder (microscopic appearance)	31
• Fig. (14): Squamous cell carcinoma of the bladder (gross appearance)	32
• Fig. (15): Adenocarcinoma of the bladder (microscopic appearance)	35
• Fig. (16): Etiologic pathway of bladder carcinogenesis	44

• Fig. (17): Picture of normal cells and high grade carcinoma in papanicolaou cytology	48
• Fig. (18): Hochest 33258-stained cell from a high grade transitional cell carcinoma	50
• Fig. (19): Fluorescence and feulgen cytology	52
• Fig. (20): Cystoscopy for a case of papillary transitional cell carcinoma	53
• Fig. (21): Intravenous pyelogram (IVP) of bladder cancer	56
• Fig. (22, 23, 24): CT & MRI of bladder cancer	59, 61, 61
• Fig. (25): Staging of bladder cancer	65
• Fig. (26): Isodose curves for anteroposterior (AP) and two lateral portals with wedges, using 18-MV photons to deliver 6000 cGy to the bladder and reduced AP portal for a 500-cGy boost to the	81
• Fig. (27): Radiation treatment portals for bladder cancer	84

List of tables

	Page
• Table (1): Relative frequency of bladder cancer in Ain Shams University Hospitals	15
• Table (2): Classification of primary carcinomas of the urinary bladder	24
• Table (3): Comparison of tumor staging systems for bladder tumors	67
• Table (4): Methods of urinary diversion	74
• Table (5): Acturial 5-year survival in two series of patients with different histopathological types of cancer bladder receiving same treatment (Cystectomy + postoperative radiotherapy)	93
• Table (6): Single agents chemotherapy for urothelial tract tumors	124
• Table (7): New agents tested in previously treated patients	125
• Fig. (8): New agents tested in previously untreated patients	125
• Table (9): Combination chemotherapy regimens	135
• Table (10): Randomized trials of neoadjuvant chemotherapy for invasive bladder cancer	140
• Table (11): Main side effects of commonly used chemotherapy in treatment of bladder cancer	144
• Table (12): Treatment options for muscle infiltrating disease	150

list of abbreviations

<i>CR</i>	<i>Complete response</i>
<i>CI</i>	<i>Confidence interval</i>
<i>G- CSF</i>	<i>Granulocyte colony stimulating factor</i>
<i>MMC</i>	<i>Mitomycin</i>
<i>PR</i>	<i>Partial response</i>
<i>RT</i>	<i>Radiation therapy</i>
<i>RR</i>	<i>Response rate</i>
<i>TCC</i>	<i>Transitional cell carcinoma</i>

